Literature DB >> 19267860

Mechanisms of penile fibrosis.

Nestor F Gonzalez-Cadavid1.   

Abstract

INTRODUCTION: Penile fibrosis has been conceptually identified with the plaque that develops in the tunica albuginea in Peyronie's disease (PD), or with localized processes induced in the corpora cavernosa by ischemic or traumatic events. Recently, it has been proposed that a diffuse, progressive, and milder intracorporal fibrosis, which affects also the media of the penile arteries, is responsible for vasculogenic erectile dysfunction (ED) associated with aging, smoking, diabetes, hypertension, and post-radical prostatectomy. These processes differ in etiology, time course, target cells, and treatment, but have many features in common. AIM: To review the literature pertaining to fibrosis in the penis, related to PD and ED.
METHODS: PubMed search for pertinent publications mainly during 2001-2008.
RESULTS: This review focuses initially on PD and then deals with studies on ED in animal and cell culture models, discussing some of the pathophysiological similarities between tunical fibrosis in PD and corporal fibrosis in corporal veno-occlusive dysfunction (CVOD), and emerging therapeutic strategies. The role of profibrotic factors, the excessive deposit of collagen fibers and other extracellular matrix, the appearance of a synthetic cell phenotype in smooth muscle cells or the onset of a fibroblast-myofibroblast transition, and in the case of the corporal or penile arterial tissue the reduction of the smooth muscle cellular compartment, are discussed. This histopathology leads either to localized plaques or nodules in penile tissues, or to the diffuse fibrosis causing impairment of tissue compliance that underlies CVOD and arteriogenic ED. The antifibrotic role of the sustained stimulation of the nitric oxide/cyclic guanosine monophosphate pathway in the penis and its possible relevance to exogenous and endogenous stem cell differentiation is also briefly presented.
CONCLUSIONS: Fibrotic processes in penile tissues share a similar cellular and molecular pathophysiology and common endogenous mechanisms of defense that have inspired novel pharmacological experimental approaches.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267860     DOI: 10.1111/j.1743-6109.2008.01195.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  41 in total

1.  Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunction.

Authors:  Maarten Albersen; Guiting Lin; Thomas M Fandel; Haiyang Zhang; Xuefeng Qiu; Ching-Shwun Lin; Tom F Lue
Journal:  Urology       Date:  2011-05-31       Impact factor: 2.649

Review 2.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

3.  Separate or combined treatments with daily sildenafil, molsidomine, or muscle-derived stem cells prevent erectile dysfunction in a rat model of cavernosal nerve damage.

Authors:  Istvan Kovanecz; Steve Rivera; Gaby Nolazco; Dolores Vernet; Denesse Segura; Sahir Gharib; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2012-09-13       Impact factor: 3.802

Review 4.  Surgical management of Peyronie's disease.

Authors:  Uwais B Zaid; Amjad Alwaal; Xiaoyu Zhang; Tom F Lue
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

5.  Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix.

Authors:  Alan W Shindel; Guiting Lin; Hongxiu Ning; Lia Banie; Yun-Ching Huang; Gang Liu; Ching-Shwun Lin; Tom F Lue
Journal:  J Sex Med       Date:  2010-03-30       Impact factor: 3.802

6.  Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice.

Authors:  Monica G Ferrini; Joanne Moon; Steve Rivera; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  BJU Int       Date:  2011-08-18       Impact factor: 5.588

7.  Recombinant PAI-1 therapy restores myoendothelial junctions and erectile function in PAI-1-deficient mice.

Authors:  P K Kavoussi; K Heberlein; A C Straub; G J Lowe; J L Oliver; R P Smith; W D Steers; B H Annex; B E Isakson; J J Lysiak
Journal:  Andrologia       Date:  2014-12-29       Impact factor: 2.775

8.  Intratunical injection of autologous adipose stromal vascular fraction reduces collagen III expression in a rat model of chronic penile fibrosis.

Authors:  Lukman Hakim; Salvatore Fiorenzo; Petter Hedlund; Francesco Montorsi; Trinity J Bivalacqua; Dirk De Ridder; Emmanuel Weyne; David Ralph; Giulio Garaffa; Asif Muneer; Steven Joniau; Maarten Albersen; Fabio Castiglione
Journal:  Int J Impot Res       Date:  2019-04-15       Impact factor: 2.896

9.  The direction and severity of penile curvature does not have an impact on concomitant vasculogenic erectile dysfunction in patients with Peyronie's disease.

Authors:  E C Serefoglu; L Trost; S C Sikka; W J G Hellstrom
Journal:  Int J Impot Res       Date:  2014-07-17       Impact factor: 2.896

Review 10.  Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction.

Authors:  Biljana Musicki; Anthony J Bella; Trinity J Bivalacqua; Kelvin P Davies; Michael E DiSanto; Nestor F Gonzalez-Cadavid; Johanna L Hannan; Noel N Kim; Carol A Podlasek; Christopher J Wingard; Arthur L Burnett
Journal:  J Sex Med       Date:  2015-12-08       Impact factor: 3.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.